utilizing science & technology and innovation for development transcatheter therapies for...
TRANSCRIPT
![Page 1: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/1.jpg)
Utilizing Science & Technology and Innovation for
DevelopmentTranscatheter Therapies For Congenital & Structural Heart Disease
Marriott Hotel- Amman, August 12th , 2015
![Page 2: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/2.jpg)
Project Team
![Page 3: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/3.jpg)
Brief Description
1. Imad Al Haddad, MD2. Ramzi Tabbalat, MD-
3. Abdel Fatah Abu Haweleh, MD
4. Iyad Al Ammouri, MD
![Page 4: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/4.jpg)
Justifications
Scope of the Problem!1. CHD: Currently, there are more than one million adult patients with congenital heart disease (un-repaired, repaired, and palliated) in the US
2. SHD: AS patients; MR patients; Afib Patients; etc! Millions of patients.
![Page 5: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/5.jpg)
The Team1. Interventional Adult Cardiologist-Expertise in SHD2. Interventional Pediatric Cardiologist3. Cardiac Surgeon-Expertise in CHD & Valve disease4. Echocardiographer-Expertise in CHD/SHD5. Anesthesia-Expertise in CHD/SHD6. Nurses/Techs/Perfusionists/etc
![Page 6: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/6.jpg)
SHD: Based on AnatomyA. Aortic Valve StenosisB. Mitral Valve Regurgitation/StenosisC. LAA in Afib PatientsD. Pulmonary Valve Regurgitation/StenosisE. Miscellaneous-Paravalvar leaks, aneurysms, etc
![Page 7: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/7.jpg)
Calcific AS
![Page 8: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/8.jpg)
Calcific AS
![Page 9: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/9.jpg)
High Risk Patients
![Page 10: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/10.jpg)
Inoperable Patients
![Page 11: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/11.jpg)
Potential Patients
AS Prevalence based on Olmsted county data and US population. More than half of the severe AS are >75 yrs.
![Page 12: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/12.jpg)
Potential Patients in Jordan
We need to do a prevalence study in the Kingdom!
![Page 13: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/13.jpg)
At least 30% with severe symptomatic AS are untreated
![Page 14: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/14.jpg)
![Page 15: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/15.jpg)
Other Valves
Direct FlowPorticoLotusOthers
![Page 16: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/16.jpg)
![Page 17: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/17.jpg)
![Page 18: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/18.jpg)
![Page 19: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/19.jpg)
![Page 20: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/20.jpg)
Objectives
1. Study the prevalence of Aortic Valve Disease in Jordan2. Determine the number of patients who undergo surgery
each year in Jordan for AVR3. Formulate a Heart Team that can manage all these
patients.
![Page 21: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/21.jpg)
Mitral Valve Disease
1. Study the prevalence of Aortic Valve Disease in Jordan2. Determine the number of patients who undergo surgery
each year in Jordan for AVR3. Formulate a Heart Team that can manage all these
patients.
![Page 22: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/22.jpg)
Mitral RegurgitationOne of the commonest forms of valvular heart diseaseUp to 12 % of patients after MI have moderate-to-severeMR
15-20% of patients with heart failure have moderate-tosevere mitral valve regurgitation
Up to 9.3% of population >75 years old have it.
![Page 23: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/23.jpg)
Mitral Valve Apparatus
![Page 24: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/24.jpg)
Survival After Surgery for MR
![Page 25: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/25.jpg)
MVR-Valves
![Page 26: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/26.jpg)
Results of MVR
Substantially improves survivalImproves clinical statusImproves quality of lifeImproves exercise toleranceImproves pulmonary hypertensionImproves LV end-diastolic volume and massContractile function also improves
![Page 27: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/27.jpg)
Major Complications with MVR
3% operative mortality7.3% prolonged ventilatory support (>24 H)2.6% acute renal failure1.4% major stroke6.3% pre-discharge reoperation5% thromboembolism within 5 years2-10% conversion to mitral valve replacementUp to 30% recurrent mitral regurgitation
![Page 28: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/28.jpg)
Surgery for chronic MR
Average in-hospital mortality for patients >65 y/o, 10.1-20.5%
Up to 1/3 of patients with severe valvular heart disease never undergo surgery
50% patients with severe symptomatic mitral regurgitation denied surgery
![Page 29: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/29.jpg)
Catheter Based Mitral Valve Repair
Provides less invasive alternative to surgical mitral valve repairAvoids the upfront morbidity and mortality of surgical mitral valveRepairProvides treatment option for elderly patients denied conventional surgeryProvides alternative therapy for patients with co-morbidities (high risk for conventional surgery)
![Page 30: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/30.jpg)
![Page 31: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/31.jpg)
Objectives
1. Study the prevalence of Mitral Valve Disease in Jordan2. Determine the number of patients who undergo surgery
each year in Jordan for MVR3. Formulate a Heart Team that can manage all these
patients.
![Page 32: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/32.jpg)
Pulmonary Regurgitation
![Page 33: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/33.jpg)
Conduit Types HomograftCloth tube conduit – porcine valve mounted into polyester tube Medtronic Contegra – bovine jugular vein Conduit/valve stenosis is primary failure mode
![Page 34: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/34.jpg)
![Page 35: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/35.jpg)
![Page 36: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/36.jpg)
Indications For PVRSevere PR in patients with NYHA class II or III symptomsIf Asymptomatic: Regurgitant fraction >35%; RVEDV >150 ml/m2; RV EF <40%; QRS duration >180 msec
Bonow R et al: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. JACC 2006;48:e1-e148
![Page 37: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/37.jpg)
The Melody Valve
![Page 38: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/38.jpg)
Bonhoeffer Was the 1st in the world to implant a percutaneous valve in a human! Pediatric Cardiologist!!!!Implanted in >8000 patients in the Pulmonic position.Bovine jugular vein valve sutured onto a platinum iridium stentUsing balloon in balloon from NuMEDHand crimping stent onto balloonsRequires 22 Fr delivery sheath.
![Page 39: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/39.jpg)
Three bovine pericardial valve leafletsStainless steel initially, then cobalt chromium stent frameNow available in 20, 23, 26 and 29 mm diameters.Height 14-19mm longE-sheath: 18-20 Fr
The Edwards Sapien THV
![Page 40: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/40.jpg)
![Page 41: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/41.jpg)
![Page 42: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/42.jpg)
Objectives
1. Study the prevalence of patients in Jordan with CHD that require a pulmonic valve
2. Formulate a Heart Team that can manage all these patients.
![Page 43: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/43.jpg)
Other Conditions
Atrial Fibrillation & Stroke
![Page 44: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/44.jpg)
LAA
![Page 45: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/45.jpg)
LAA
![Page 46: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/46.jpg)
Objectives
1. Study the prevalence of patients in Jordan with Afib2. Formulate a Heart Team that can manage all these
patients.
![Page 47: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/47.jpg)
Scope of work/DurationEstimated Budget
Scope of work: 1. Epidemiological studies to determine prevalence of conditions
Duration: This will take few years
Estimated Budget : 1. Study: Unknown2. Cost of valves: expensive
![Page 48: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/48.jpg)
Methodology of Implementation
● Determine on a site where all operations should be done ● Formulate the Heart team ● Training of the team ● Work with the industry to provide devices/valves at a reasonable price
![Page 49: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/49.jpg)
Expected output
● Patients in Jordan will benefit from cutting edge technologyLength of hospital stay will be reducedOverall resources in Jordan will be savedThis will put Jordan on the map in this area.
![Page 50: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/50.jpg)
Impact
Reduction of Morbidity & Mortality from open heart surgery
![Page 51: Utilizing Science & Technology and Innovation for Development Transcatheter Therapies For Congenital & Structural Heart Disease Marriott Hotel- Amman,](https://reader035.vdocuments.mx/reader035/viewer/2022062516/56649e705503460f94b6e901/html5/thumbnails/51.jpg)
Sustainability
With continued financial support and team spirit, this project can last indefinitely.